In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ameren's current price exceeds its high-confidence weighted fair value by about 38.5%, indicating potential overvaluation. DCF shows significant negative valuation, contrasting with positive P/E and EV/EBITDA estimates, suggesting model discrepancies. Low financial health and 1.00 growth score highlight risk amid limited upside from Monte Carlo analysis.